🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer

Recruitingn/aAges 18 Years - anyAllyi shen
NCT07596654 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Limited-stage small cell esophageal carcinoma (LS-SCEC) is a rare and highly aggressive malignancy with poor prognosis and no established standard treatment strategy. Due to its low incidence, current evidence is mainly derived from small retrospective studies, and the role of surgery in multimodal treatment remains controversial. In particular, the survival benefit of surgical treatment compared with definitive non-surgical therapy has not been fully clarified. This single-center retrospective cohort study aims to evaluate the impact of surgical versus non-surgical treatment strategies on survival outcomes in patients with LS-SCEC. Patients receiving surgical treatment, including surgery alone, neoadjuvant therapy followed by surgery, or surgery followed by adjuvant therapy, will be compared with patients receiving definitive non-surgical treatment, including chemoradiotherapy-based ap

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients pathologically diagnosed with primary small cell esophageal carcinoma (SCEC). * Patients classified as having limited-stage disease at initial diagnosis, defined as tumor confined to the esophagus and/or regional lymph nodes without evidence of distant metastasis. * Patients who received definitive treatment at the study institution, including surgical treatment (with or without neoadjuvant or adjuvant therapy) or definitive non-surgical treatment such as chemoradiotherapy-based therapy. * Patients with complete baseline clinicopathological and treatment information available in the medical records. * Patients with available follow-up and survival outcome data. Exclusion Criteria: * Patients with extensive-stage disease or distant metastasis at diagnosis. * Patients with mixed histological subtypes in which small cell carcinoma was not the predominant component. * Patients who received palliative treatment only. * Patients with a history of other active malignant tumors within the previous 5 years. * Patients with incomplete key clinical, treatment, or follow-up data. * Patients under 18 years old.
💊

What it tests

  • Not listed
📍

Where

1 site
Jinling Hospital, Nanjing, Jiangsu Province, China.
Nanjing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy